Clinical trial
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
NCT04848272 is registered in ClinicalTrials.gov with St Vincent's Institute of Medical Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
- Lead sponsor
- St Vincent's Institute of Medical Research
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 9, 2021
- Completion date
- December 31, 2024
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.